JPWO2021243298A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021243298A5 JPWO2021243298A5 JP2022573609A JP2022573609A JPWO2021243298A5 JP WO2021243298 A5 JPWO2021243298 A5 JP WO2021243298A5 JP 2022573609 A JP2022573609 A JP 2022573609A JP 2022573609 A JP2022573609 A JP 2022573609A JP WO2021243298 A5 JPWO2021243298 A5 JP WO2021243298A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- administration
- april
- loading
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- 238000012423 maintenance Methods 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 4
- 229930064664 L-arginine Natural products 0.000 claims 4
- 235000014852 L-arginine Nutrition 0.000 claims 4
- 229960002885 histidine Drugs 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 239000000600 sorbitol Substances 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062704831P | 2020-05-29 | 2020-05-29 | |
| US62/704,831 | 2020-05-29 | ||
| PCT/US2021/035011 WO2021243298A1 (en) | 2020-05-29 | 2021-05-28 | Methods of treating iga nephropathy with an april binding antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527563A JP2023527563A (ja) | 2023-06-29 |
| JPWO2021243298A5 true JPWO2021243298A5 (lt) | 2024-06-06 |
Family
ID=78722933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573609A Pending JP2023527563A (ja) | 2020-05-29 | 2021-05-28 | ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210379183A1 (lt) |
| EP (1) | EP4157339A4 (lt) |
| JP (1) | JP2023527563A (lt) |
| KR (1) | KR20230017223A (lt) |
| CN (1) | CN115996748A (lt) |
| AU (1) | AU2021279035A1 (lt) |
| BR (1) | BR112022024262A2 (lt) |
| CA (1) | CA3179812A1 (lt) |
| IL (1) | IL298370A (lt) |
| MX (1) | MX2022014995A (lt) |
| WO (1) | WO2021243298A1 (lt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| WO2024092240A1 (en) | 2022-10-28 | 2024-05-02 | Chinook Therapeutics, Inc. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| WO2024099272A1 (zh) * | 2022-11-07 | 2024-05-16 | 信瑞诺医药（上海）有限公司 | 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| PT2139517E (pt) * | 2007-03-27 | 2013-07-11 | Ares Trading Sa | Combinação de inibição de blys e micofenolato mofetil para tratamento de doença auto-imune |
| AU2010220421B9 (en) * | 2009-03-02 | 2015-03-05 | Aduro Biotech Holdings, Europe B.V. | Antibodies against a proliferating inducing ligand (APRIL) |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| CN108430503A (zh) * | 2015-10-28 | 2018-08-21 | 艾杜罗生物科技公司 | 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| WO2018201064A1 (en) * | 2017-04-28 | 2018-11-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| CA3079946A1 (en) * | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
-
2021
- 2021-05-28 WO PCT/US2021/035011 patent/WO2021243298A1/en unknown
- 2021-05-28 US US17/334,590 patent/US20210379183A1/en active Pending
- 2021-05-28 CA CA3179812A patent/CA3179812A1/en active Pending
- 2021-05-28 BR BR112022024262A patent/BR112022024262A2/pt unknown
- 2021-05-28 KR KR1020227043773A patent/KR20230017223A/ko active Search and Examination
- 2021-05-28 AU AU2021279035A patent/AU2021279035A1/en active Pending
- 2021-05-28 MX MX2022014995A patent/MX2022014995A/es unknown
- 2021-05-28 EP EP21813022.7A patent/EP4157339A4/en active Pending
- 2021-05-28 CN CN202180046732.2A patent/CN115996748A/zh active Pending
- 2021-05-28 JP JP2022573609A patent/JP2023527563A/ja active Pending
- 2021-05-28 IL IL298370A patent/IL298370A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200384108A1 (en) | Liquid il-1 beta antibody formulation having ph of 5.5 to 7.0 | |
| US7740842B2 (en) | Stable liquid formulations of antibodies | |
| TWI806150B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| US11498959B2 (en) | Anti-CGRP antibody formulation | |
| CN106604750B (zh) | 治疗骨髓瘤 | |
| JP2024026214A5 (lt) | ||
| CN108601831A (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| JP2002544174A5 (lt) | ||
| JP2015512392A5 (lt) | ||
| RU2007124933A (ru) | Стабилизированные жидкие полипептидные составы | |
| AU2004317520B2 (en) | Stable injectable diclofenac compositions | |
| JP2014530917A5 (lt) | ||
| JP2016514132A5 (lt) | ||
| KR20140025314A (ko) | 복합 조성물 | |
| KR20150032941A (ko) | 약학 제제 | |
| WO2022135395A1 (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| KR20200014738A (ko) | 안정한 항-osmr 항체 제형 | |
| JPWO2021243298A5 (lt) | ||
| JP6480154B2 (ja) | エタネルセプトの凍結乾燥製剤 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2020531523A5 (lt) | ||
| JPWO2021123902A5 (lt) | ||
| US20210393777A1 (en) | Stable preparation comprising anti-pcsk9 antibody | |
| IL312401A (en) | Methods for treating Crohn's disease with a specific anti-IL23 antibody | |
| RU2021135507A (ru) | Антитела к cd40 для применения в лечении t1dm и инсулита |